N/A
Completed N=6
Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI
Facial Neuropathy
Source: ClinicalTrials.gov NCT00243152 ↗
Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Blood Oxygenation Level-dependent (BOLD) Changes in Neural Pain Circuitry Following Treatment With Lamotrigine During Experimentally Induced Pain States — -2.9294; -2.7323; -2.5114; -3.033 Z-statistic
Summary
The aim of this project is to evaluate the effects of the anticonvulsant drug lamotrigine (trade name Lamictal) on neuropathic facial pain or neuralgia using functional magnetic resonance imaging (fMRI).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Oxygenation Level-dependent (BOLD) Changes in Neural Pain Circuitry Following Treatment With Lamotrigine During Experimentally Induced Pain States |
-2.9294; -2.7323; -2.5114; -3.033; 3.905; -3.791 | — |
| SECONDARY Subjective Ratings of Pain During Magnetic Resonance Scanning |
5.5; 3.2; 4; 3; 2.5; 2.1 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
- 18-60 years of age
- Right-handed non-smokers
- Diagnosed with facial pain
- Continuous pain for more than 3 months
- Spontaneous pain greater than 3 of 10
- Allodynia to brush greater than 5 of 10
Exclusion Criteria
- Medications
- Depression
- Significant medical problems
- Claustrophobia
- Abnormal EKG
- Significant drug or alcohol history
- Positive drug screen
- Weight greater than 285 lbs
- History of allergy to anticonvulsants
- Tattoos with metallic ink on upper body
- Any neurostimulator devices, or metal cochlear, ocular, or cardiac implants or other metal near vital areas
- Exposure to shrapnel or metal filings
- Other metallic surgical hardware
Data sourced from ClinicalTrials.gov (NCT00243152). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.